Search Site

Trends banner

Oracle shares up 35%

Huge AI contracts lead to the surge.

ADCB to raise $1.66bn

The rights issue aimed at boosting growth.

EGA H1 revenue $4.11bn

Net profit before GAC $445 million.

Borouge to pay $660m H1 dividend

Its net profit for H1 was $474 million.

TAQA secures $2.31bn loan

It will be utilized in a phased manner.

Vaccine factory to come up in Khazaen City with $52m outlay

The rise in producer price index was driven by a hike in oil and gas prices.
  • The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi
  • Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City

The Khazaen Economic City in Oman has signed an agreement with biopharmaceuticals business company Opal to establish a factory for the production of biological human vaccines, official sources have said.

The deal was signed in Muscat on Wednesday, and has an outlay of OMR20 million (around $52 million), said the sources.

The first phase of the project is expected to be set up on a total area of 37,000 square meters.

The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi.

Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City.

He added that it targets local and international markets.

The agreement, Al Thuhli added, comes as part of Khazaen’s efforts in attracting local and international investments.